Compile Data Set for Download or QSAR
Report error Found 2926 of ic50 data for complexid = 97,50014798
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601933(US11643416, Compound 1 | 4-((6'-hydroxy-8'-oxo-7',...)
Affinity DataIC50: 0.160nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM6878(5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphen...)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of GST-tagged CDK2/cyclin A2 (unknown origin) expressed in Escherichia coli using histone H1 as substrate in presence of [gamma-33P]-ATP b...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642760(1-isopropyl-N-(1-(methylsulfonyl)piperidin-4-yl)-1...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642762(N-(1-(cyclopropylsulfonyl)piperidin-4-yl)-1-isopro...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642766(4-((1-isopropyl-1H-[1,2,3]triazolo[4,5-h]quinazoli...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642767(US20230416271, Compound II.21)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642768(US20230416271, Compound II.22)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642760(1-isopropyl-N-(1-(methylsulfonyl)piperidin-4-yl)-1...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642773(4-(difluoromethyl)-1-isopropyl-N-(1-(methylsulfony...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642774(4-(difluoromethyl)-N-(1-(ethylsulfonyl)piperidin-4...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642775(N-(1-(cyclopropylsulfonyl)piperidin-4-yl)-4-(diflu...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642777(1-isopropyl-N-(1-(methylsulfonyl)piperidin-4-yl)-4...)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642778(US20230416271, Compound II.32)
Affinity DataIC50: 0.200nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM621171(US20230303564, Compound 4)
Affinity DataIC50: 0.270nMAssay Description:Enzymes, substrates, ATP, and inhibitors were diluted by kinase buffer in the kit. The compounds to be tested were diluted 5-fold with a multi-channe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7167(3-(4-sulfamoylphenyl)-3,4,10,11-tetraazatricyclo[7...)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzymes and substrates in the presence ATP/[gamma-33P] ATP. After in...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM6867(4-({5-amino-1-[(2,6-difluoro-3-methylphenyl)carbon...)
Affinity DataIC50: 0.300nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642761(N-(1-(ethylsulfonyl)piperidin-4-yl)-1-isopropyl-1H...)
Affinity DataIC50: 0.300nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642776(4-(difluoromethyl)-N-(1-((difluoromethyl)sulfonyl)...)
Affinity DataIC50: 0.300nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642779(US20230416271, Compound II.33)
Affinity DataIC50: 0.300nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642784(N-(1-(cyclopropylsulfonyl)piperidin-4-yl)-1-isopro...)
Affinity DataIC50: 0.300nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM8411(4-{[3-(4-nitrophenyl)-1H-pyrazol-5-yl]amino}benzen...)
Affinity DataIC50: 0.330nMpH: 7.5 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzymes and substrates in the presence 1.4 uM ATP/[gamma-32P] ATP. A...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM8399(4-{[3-(4-aminophenyl)-1H-pyrazol-5-yl]amino}benzen...)
Affinity DataIC50: 0.340nMpH: 7.5 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzymes and substrates in the presence 1.4 uM ATP/[gamma-32P] ATP. A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM6870(4-({5-amino-1-[(3-methylthiophen-2-yl)carbonyl]-1H...)
Affinity DataIC50: 0.400nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642765(N-(1-((difluoromethyl)sulfonyl)piperidin-4-yl)-1-i...)
Affinity DataIC50: 0.400nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642769(US20230416271, Compound II.23)
Affinity DataIC50: 0.400nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642772(1-isopropyl-4-methyl-N-(1-(methylsulfonyl)piperidi...)
Affinity DataIC50: 0.400nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601934(US11643416, Compound 2 | 4-((7'-oxo-7',8'-dihydro-...)
Affinity DataIC50: 0.400nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM6878(5-amino-N-(2,6-difluorophenyl)-3-[(4-sulfamoylphen...)
Affinity DataIC50: 0.5nMAssay Description:The enzyme was assayed with a biotinylated peptide substrate and test compounds in the presence of 10 uM ATP/[gamma-33P]ATP in a streptavidin coated ...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642760(1-isopropyl-N-(1-(methylsulfonyl)piperidin-4-yl)-1...)
Affinity DataIC50: 0.5nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM642785(N-(1-((difluoromethyl)sulfonyl)piperidin-4-yl)-1-i...)
Affinity DataIC50: 0.5nMAssay Description:Assay of Kinase Activity The inhibitory effect of compounds against the kinase CDK4/cyclin D3 was detected by Caliper Mobility Shift Assay method. Th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM621172(US20230303564, Compound 8 | US20230303564, Compoun...)
Affinity DataIC50: 0.520nMAssay Description:Enzymes, substrates, ATP, and inhibitors were diluted by kinase buffer in the kit. The compounds to be tested were diluted 5-fold with a multi-channe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7751((12Z)-12-{[(4-{[2-(2-hydroxyethoxy)ethyl]sulfamoyl...)
Affinity DataIC50: 0.540nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzymes and substrates in the presence 1.4 uM ATP/[gamma-32P] ATP. A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM621170(US20230303564, Compound 1)
Affinity DataIC50: 0.560nMAssay Description:Enzymes, substrates, ATP, and inhibitors were diluted by kinase buffer in the kit. The compounds to be tested were diluted 5-fold with a multi-channe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of human CDK2/cyclin-A using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, Calif.) to determine their inhibitory effect on these CDKs....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM601953(US11643416, Compound 55 | 2'-((4-(piperazine-1- ca...)
Affinity DataIC50: 0.600nMAssay Description:Selected compounds disclosed herein were tested in kinase assays by Nanosyn (Santa Clara, CA) to determine their inhibitory effect on these CDKs. The...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50511934(CHEMBL4590821)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human CDK2/Cyclin A expressed in baculovirus infected Sf9 insect cellsMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM50573929(CHEMBL4848734)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human CDK2/cyclinA using Histone H1 as substrate incubated for 2 hrs by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM525717(US11174252, Compound 12)
Affinity DataIC50: 0.700nMAssay Description:CDK5 (p25): IC50 values of compounds against CDK5 (p25) were determined by Z′-LYTE™. These screening assays were performed at Invitrogen L...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7533(2,6,9-Trisubstituted purine deriv. 28 | (2R)-2-[[6...)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of CDK2/cyclin A (unknown origin) expressed in baculovirus infected Sf9 cells using histone H1 as substrate incubated for 10 mins in prese...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 0.720nMAssay Description:Inhibition of CDK2/cyclin A (unknown origin)More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM2579(CHEMBL388978 | Staurosporine, 8 | Staurosporin, 4 ...)
Affinity DataIC50: 0.727nMAssay Description:Inhibition of human CDK2/cyclin-A using histone H1 as substrate by [gamma-33P]-ATP assayMore data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM621172(US20230303564, Compound 8 | US20230303564, Compoun...)
Affinity DataIC50: 0.730nMAssay Description:Enzymes, substrates, ATP, and inhibitors were diluted by kinase buffer in the kit. The compounds to be tested were diluted 5-fold with a multi-channe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM253929(US9464092, U | US9527857, U)
Affinity DataIC50: 0.857nMAssay Description:Selected compounds disclosed herein were tested in CDK4/cyclinD1, CDK6/CycD3 CDK2/CycA and CDK2/cyclinE kinase assays by Nanosyn (Santa Clara, Calif....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM7177(3-(4-methanesulfonylphenyl)-3,4,10,11-tetraazatric...)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzymes and substrates in the presence ATP/[gamma-33P] ATP. After in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM8129(4-[(4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-y...)
Affinity DataIC50: 1nMpH: 7.2 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM8139(N-(3,4-dichlorophenyl)-4-{pyrazolo[1,5-a]pyridazin...)
Affinity DataIC50: 1nMpH: 7.2 T: 2°CAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
G1 Therapeutics

US Patent
LigandPNGBDBM8144(N-(3,5-difluorophenyl)-4-{pyrazolo[1,5-a]pyridazin...)
Affinity DataIC50: 1nMAssay Description:The biochemical activity of compounds was determined by incubation with specific enzyme and substrate in the presence 2.5 uM ATP/ [gamma-32P] ATP. Af...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
PubMed
Displayed 1 to 50 (of 2926 total ) | Next | Last >>
Jump to: